The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives? In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within five years. “Five years after the initial accelerated approval, you should have a definitive answer,” said Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research. “Thousands of people are getting those drugs. That seems a mistake if we don’t know whether they work or not.” The program was created in 1992 to speed access to HIV drugs. Today, 85% of accelerated approvals go to cancer drugs. It allows the FDA to grant early approval to drugs that show promising initial results for treating debilitating or fatal diseases. In exchange, drug companies are expected to do rigorous testing and produce better evidence before gaining full approval. |
Chinese, Dominican presidents exchange congratulations on 20th anniversary of diplomatic tiesChina Overall 54th Asian Para Games Opens in Hangzhou, E ChinaRussia mourns victims of deadly terrorist attackAnimation Featuring China's Sanxingdui Culture Set to Hit Big ScreenChina Invests Heavily in Tibet's Cultural Heritage AffairsXinhua Headlines: A Vibrant City on Ancient Silk Road — Kashgar in the Eyes of Foreign TouristsCounty in E China Develops Rope Net IndustryU.S. Students Participate in China Education Tour in Sichuan, SW ChinaChina Launches National Advisory Committee for Students' Mental Health